Pharma Pulse: Overton's FDA Bid, EVERSANA's AI Expansion, and a Landmark Cancer Vaccine

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines.

First up, the White House has named its pick to run the FDA.

President Trump has nominated Heidi Overton, deputy director of the White House Domestic Policy Council, to serve as FDA commissioner, filling a post vacant since Marty Makary's resignation in May. Overton, a physician who has advised the administration on drug pricing and vaccine policy, previously led the America First Policy Institute's Center for a Healthy America. The nomination follows reports that acting commissioner Kyle Diamantas turned down the job more than once. As a Senate-confirmed position, her path isn't guaranteed; confirmation hearings are expected to test her alignment with the administration's health agenda.

Next, EVERSANA is expanding its AI-powered commercialization platform.

EVERSANA announced expanded capabilities for its AI-powered commercialization platform, EVERSANA AI Agency, pushing beyond its original marketing-agency roots into medical affairs, market research and field sales engagement, and other commercial functions.¹ New tools now cover medical information, market research, and MLR automation and analytics, with additional innovations in development across market access, patient services, sales enablement and other functions. CEO Mark Thierer framed the move as helping clients scale AI past isolated pilots toward a connected operating model, while maintaining the governance, compliance and scientific rigor the industry requires.

Also this week, a milestone thirteen years in the making for personalized cancer treatment.

Merck and Moderna announced that intismeran autogene, their individualized mRNA therapy, met its primary and a key secondary endpoint in the Phase 3 INTerpath-001 trial, the first positive late-stage result ever for an mRNA-based cancer treatment. Combined with Keytruda, the therapy significantly improved recurrence-free and distant metastasis-free survival in resected, high-risk melanoma patients versus Keytruda alone. The therapy is built individually from each patient's tumor sample. Moderna's shares added roughly $40 billion in market cap on the news, and Merck climbed as much as 11%. Full data and regulatory filing discussions are expected at an upcoming international medical meeting.

Lastly, the cold chain map gets another stop in Southeast Asia.

IAG Cargo has added Kuala Lumpur International Airport to its Constant Climate network, its 13th Asia-Pacific station and roughly 100th globally. The GDP-certified stop handles active and passive temperature-controlled pharma shipments and connects via a daily Heathrow flight timed for same-day onward transfers. The move tracks regional demand: Asia-Pacific's pharma cold chain segment is projected to grow 10.9% annually through 2032, the fastest of any product category in the region. IAG Cargo also cited its new joint business with Qatar Airways Cargo and MASkargo as deepening Southeast Asia connectivity.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening, until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.

Reference

1. EVERSANA. EVERSANA Expands AI-Powered Commercialization Platform with New Capabilities Across Medical Affairs, Market Research and Commercial Operations. Press Release. Published August 20, 2026.